Rapid Readout: Angiopoietin-2 (Ang2) Inhibition in the Treatment of Diabetic Macular Edema and Exudative AMD.

March 22, 2021

Anat Loewenstein, MD, MHA, discusses data from the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium on angiopoietin-2/VEGF-A dual inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.

Study targets strategies for CI-DMO

March 22, 2021

In the DRCR Retina Network Protocol V, which studied management strategies for eyes with centre-involving DMO and good visual acuity, the majority of eyes randomly assigned to initial observation completed the 2-year study without needing anti-VEGF therapy for vision loss and nearly one-third had spontaneous resolution of DMO.

Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives

March 03, 2021

Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.

Learning the basics of age-related macular degeneration

February 03, 2021

Ian C. Han, MD, assistant professor in the Department of Ophthalmology and Visual Sciences, Institute for Vision Research, University of Iowa Hospital and Clinics, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.